Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Fred Hutchinson Cancer Center
Children's Oncology Group
Institute of Hematology & Blood Diseases Hospital, China
Astellas Pharma Inc
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital
Delta-Fly Pharma, Inc.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Stanford University
Shanghai Jiao Tong University School of Medicine